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Neuropharmacological journey in monoaminergic fields. 
 
The extensive research conducted on monoaminergic systems including dopaminergic, 
serotonergic, noradrenergic, histaminergic and, to a lower extent melatonergic systems, continues to 
expand our current knowledge. The topic has enormous health, economic, scientific and conceptual 
stakes, with engagement across disciplines covering medicinal chemistry to neuropsychiatric and 
neurological diseases. This special issue presents scientific updates with in depth analyses on selected 
aspects of this complicated topic.  
Antipsychotic and antidepressant drugs opened the way to intensive research on monoaminergic 
systems. The serendipitous discoveries of these treatments in the 1950s led to the identification of  
monoaminergic systems as the main origin of their efficacy. Under the scope of neurosciences and 
biological psychiatry, much fundamental research has identified the proteins involved in the function of 
monoaminergic systems. As illustrated on Figure 1, each monoamine can act on a variety of receptors 
distinctly expressed in the brain, and displaying some selectivity for each monoamine. While the 
picture roughly illustrates the main families of these receptors, molecular biology has revealed the 
existence of several subtypes for most of these receptors coming from alternative splicing, 
posttranscriptional and/or posttranslational processes. The identification of specific monoaminergic 
targets involved in the beneficial and side effects of these drugs has enabled medicinal chemistry to 
produce drugs favouring one or several good targets over the deleterious ones. The article by Butini et 
al is an illustration of the pharmacological profile and chemical requirements of new antipsychotic or 
anti-Parkinsonian drugs to achieve good efficacy with low or no side-effects (Butini et al., 2017). 
Several receptors or enzymes are usually targeted leading to the new popularity of multitarget drug 
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design (Millan, 2009; Ramsay et al., 2016; Weinreb et al., 2016).  
The pharmacological profile of a multi-target drug is even more complicated because the 
molecular environment of one target is specific to the cell expressing this target, leading to biased 
agonists. This means that a drug behaves differently on its target depending on the tissue. Interesting 
achievements have been obtained with drugs preferentially activating somatodendritic 5-HT1A 
autoreceptors versus heteroreceptors and vice versa that could be pertinent for the treatment of mood 
disorders or dyskinesia induced by L-DOPA. While the specifications are growing for producing newer 
drugs, the molecular pharmacology becomes more insightful in conceptualizing the partnerships of 
neurotransmitter receptors in space and time. Wirth et al. report an interesting perspective of molecular 
signalling events in the morphogenic effects of serotonin (5-HT) (Wirth et al., 2017). These effects 
include a variety of 5-HT receptors that modulate synaptogenesis, neurite outgrowth, dendritic spine 
shape and density. These regulations occur at different stages of the development, are region-dependent 
and could maintain aberrant modelling of networks and pathophysiology.  
 The refinement of pharmacological drugs has helped elucidate a better understanding of the 
pathophysiology of numerous CNS diseases. A better knowledge of pathophysiology is surely a step 
for the identification of new pharmacological targets, perhaps beyond the symptomatic treatment 
(Millan et al., 2015). At a time where the pathology-to-drug discovery approach is in expansion, our 
certitudes regarding the treatment of Parkinson’s disease and the mechanism of action of the lead 
antiparkinsonian treatment L-DOPA are disappearing. The metabolic precursor of dopamine (DA) L-
DOPA is administered to patients soon after the identification of the loss of dopamine in the putamen 
and caudate nucleus of Parkinson patients. De Deurwaerdère et al. have reported numerous data 
dampening the idea that the benefit and side effects of L-DOPA were related to an increase in DA in 
the caudate nucleus and the putamen (De Deurwaerdere et al., 2017). The mechanisms of L-DOPA 
appear to be much more subtle, widespread in the brain and distinct from dopaminergic agonists. 
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Referring again to Figure 1, it is noteworthy that monoaminergic systems share enzymes for their 
biosynthesis, the vesicular monoamine transporter for their translocation into the vesicles of exocytosis, 
enzymes for their catabolism as well transporters for the reuptake. Some transporters and enzymes are 
also present in neighbouring glial and neuronal cells. Consequently, the administration of amino acid 
precursors such as L-DOPA or drugs that act on degrading enzymes such as monoamine oxidase 
inhibitors can only result in ectopic effects.  
Serendipity has played an important role in the development of drugs aimed at treating the 
symptoms of schizophrenia, mood disorders or Parkinson’s disease. This point of view is further 
stressed in considering that diseases like Alzheimer’s disease or epilepsy still do not have 
monoaminergic-based treatments (Di Giovanni et al., 2016; Svob Strac et al., 2016). The paper by 
Simic et al recalls that Alzheimer’s disease is also marked by several perturbations of monoaminergic 
systems (Simic et al., 2017). Hopefully, the numerous clinical trials they report with monoaminergic 
drugs targeting neuroreceptors will end up soon in a more appropriate medical care of the disease. The 
other side of this thought is that it is often difficult to understand the role of monoaminergic systems in 
the benefit and side effects of efficacious therapies. Here, two articles by Faggiani and Benazzouz and 
by Galati et al., focus on the impact of deep brain stimulation of the subthalamic nucleus in the 
treatment of Parkinson’s disease with specific regards on monoamines and on non-motor and motor 
effects of the treatment, (Faggiani and Benazzouz, 2017; Stefani et al., 2017), respectively. Numerous 
neurochemical effects are triggered by the deep brain stimulation of the subthalamic nucleus on 
monoaminergic systems but the extent to which these modifications lead to therapeutic effects is still a 
matter of debate. 
At one point one may wonder why it is so difficult to progress and to understand the function of 
these systems. Maybe the organization and the morphology of these systems is a real issue. In fact, the 
cell bodies of these neurons are confined in hypothalamus (histamine), mesencephalon (DA, 5-HT)), 
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pons (5-HT) or medulla (noradrenaline) and innervate widely the entire encephalon with thousand sites 
of release for only one neuron. The neurohumoral way of contacting neurobiological networks and long 
distance neurons imply local and distal interactions. In addition, the monoaminergic systems establish 
complex interactions in the brain. De Deurwaerdère and Di Giovanni emphasise the interaction 
between 5-HT and DA systems (De Deurwaerdere and Di Giovanni, 2017). Beyond the molecular and 
cellular complexity of the mechanisms involved in the influence of 5-HT on DA neuronal function, the 
authors highlight also the multiplicity of regions and dimensions implicated in this interaction, which is 
important for the mechanism of action of antipsychotic, antidepressant, anti-Parkinsonian and anti-
addictive drugs.  
While there has been a lot of progress in molecular pharmacology, it is also mandatory to 
progress on the physiological roles of these monoaminergic systems in the brain. The 
neuropharmacological approaches brought many indications and still will bring more. Lorincz and 
Adamantidis in this issue highlight the use of new technologies such as optogenetic targeting 
specifically subsets of neurons, systems or receptors to study the function of monoaminergic systems 
(Lorincz and Adamantidis, 2017). These new approaches will shed another light on monoaminergic 
systems to better understand the efficacy of various medicines used to treat CNS diseases.  
The tale continues. 
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LEGEND TO FIGURE 1 
 
Molecular organization of central monoaminergic systems. The figure shows each monoamine 
system (dopamine, DA; noradrenaline, NA; serotonin, 5-HT; histamine); the biosynthesis, metabolism, 
the receptors and transporters. Colors are used to identify the proteins that are selective for each system 
while the black color is used for non-specific proteins. The terminals of each monoaminergic neurons 
contact post-synaptic elements in the brain that express a variety of receptors which are more or less 
specific for each monoamine. The main families are represented. Autoreceptors can be located at 
terminals and cell bodies for most monoaminergic systems. In the case of serotonergic cells, 5-HT1A 
autoreceptors are addressed at cell bodies and 5-HT1B autoreceptors are addressed at terminals; 5-HT2B 
autoreceptors would be addressed at both sites. The post-synaptic elements (neurons, glial cells) also 
express enzymes involved in the metabolism of monoamines (MAO-A/B or COMT) as well as non-
specific transporters. DBH is mainly expressed in vesicles of exocytosis in noradrenergic terminals. 
AADC, aromatic L-amino acid decarboxylase; DBH, dopamine β-hydroxylase; TPH, tryptophan 
hydroxylase; VMAT2, vesicular monoamine transporter; SERT, 5-HT transporter, DAT, DA 
transporter; NET, NA transporter; OCT, organic cation transporters; PMAT, plasma membrane 
monoamine transporter; HDC, L-histidine decarboxylase; MAO, monoamine oxidase (A or B); COMT, 
catechol-O-methyl transferase. 
 
 
 
